Hepatitis C Vaccine Phase I Clinical Trial Kicks Off in Korea
Additional clinical studies to assess INO-8000/VGX-6150, a vaccine for Hepatitis C, will also take place in the U.S. beginning in 2014.
Continue reading »Hepatitis C Treatments/Therapies
Have Quicker and More Effective Approaches Arrived for Eradicating Hepatitis C?
Oct 23, 2013
9 Comments
Two Hepatitis C drugs the FDA is reviewing have the potential to increase cure rates for the liver virus. Discover more about the experimental medications from Johnson & Johnson and Gilead Sciences, called simeprevir and sofosbuvir.
Continue reading »A New Combination of Hepatitis C Drugs Leading to High Remission Rates
Oct 16, 2013
3 Comments
In phase 2 trials, the addition of the drug danoprevir to the current treatment regimen for patients with Hepatitis C showed an 85 percent sustained virologic response rate.
Continue reading »NS5a Replication Complex Inhibitor Will Be Used in Future Studies
A combination of NS5a and Simeprevir will be used in the treatment of chronic Hepatitis C in patients with compensated liver disease. These trials will prove helpful in future developments.
Continue reading »
3 Hep C Treatment Side Effects Aided by Probiotics
Discover how probiotics can minimize the Hepatitis C treatment side effects of fatigue, nausea and low appetite.
Continue reading »Ongoing Phase II Trial: Hepatitis C Virus Undetectable in Patients
Oct 9, 2013
22 Comments
Boehringer Ingelheim, a leading pharmaceutical company, along with Presidio Pharmaceuticals, has developed a 12-week interferon-free program with promising results.
Continue reading »Sofosbuvir + Ribavirin Cures Many with Hepatitis C in Phase II Clinical Trial
Aug 28, 2013
15 Comments
Read the details about a Phase II Clinical Trial which highlights compelling evidence that interferon-free regimens can be safe and effective.
Continue reading »Interferon-Free Combination Therapy Is Effective for Hepatitis C Patients
Aug 20, 2013
41 Comments
Learn about a new interferon-free regimen that achieved sustained virologic response rates close to 70% in a phase II clinical trial.
Continue reading »Medivir Discontinues NS5A Inhibitor Program
Medivir is working on the development of a new treatment that uses the basic molecules of DNA and RNA to slow down the Hepatitis C virus.
Continue reading »Older Patients Have a Better Outcome with TVR-Based Triple Therapy
Although it has been determined that age has no impact on the outcome of triple therapy with pegylated interferon, ribavirin and telaprevir, older patients benefit more than with the traditional dual therapy.
Continue reading »
